Challenges and opportunities for siRNA-based cancer treatment

Tao Wang; Sarah Shigdar; Hadi Al Shamaileh; Michael P. Gantier; Wang Yin; Dongxi Xiang; Lan Wang; Shu Feng Zhou; Yingchun Hou; Peng Wang; Weihong Zhang; Chunwen Pu; Wei Duan

doi:10.1016/j.canlet.2016.03.045

Challenges and opportunities for siRNA-based cancer treatment

Tao Wang, Sarah Shigdar, Hadi Al Shamaileh, Michael P. Gantier, Wang Yin, Dongxi Xiang, Lan Wang, Shu Feng Zhou, Yingchun Hou, Peng Wang, Weihong Zhang, Chunwen Pu, Wei Duan

Hudson Institute - Department of Molecular and Translational Science

Research output: Contribution to journal › Short Survey › Other › peer-review

99 Citations (Scopus)

Abstract

As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored.

Original language	English
Pages (from-to)	77-83
Number of pages	7
Journal	Cancer Letters
Volume	387
DOIs	https://doi.org/10.1016/j.canlet.2016.03.045
Publication status	Published - 28 Feb 2017

Keywords

Endosome escape
EPR effect
Nanoparticle
Off-target
RNA interference
Tumour

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2016.03.045

Cite this

@article{0c2d0b4766f3436a8f1101bbb03ab0e1,

title = "Challenges and opportunities for siRNA-based cancer treatment",

abstract = "As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored.",

keywords = "Endosome escape, EPR effect, Nanoparticle, Off-target, RNA interference, Tumour",

author = "Tao Wang and Sarah Shigdar and Shamaileh, \{Hadi Al\} and Gantier, \{Michael P.\} and Wang Yin and Dongxi Xiang and Lan Wang and Zhou, \{Shu Feng\} and Yingchun Hou and Peng Wang and Weihong Zhang and Chunwen Pu and Wei Duan",

year = "2017",

month = feb,

day = "28",

doi = "10.1016/j.canlet.2016.03.045",

language = "English",

volume = "387",

pages = "77--83",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier",

}

TY - JOUR

T1 - Challenges and opportunities for siRNA-based cancer treatment

AU - Wang, Tao

AU - Shigdar, Sarah

AU - Shamaileh, Hadi Al

AU - Gantier, Michael P.

AU - Yin, Wang

AU - Xiang, Dongxi

AU - Wang, Lan

AU - Zhou, Shu Feng

AU - Hou, Yingchun

AU - Wang, Peng

AU - Zhang, Weihong

AU - Pu, Chunwen

AU - Duan, Wei

PY - 2017/2/28

Y1 - 2017/2/28

N2 - As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored.

AB - As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored.

KW - Endosome escape

KW - EPR effect

KW - Nanoparticle

KW - Off-target

KW - RNA interference

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=84975502218&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.03.045

DO - 10.1016/j.canlet.2016.03.045

M3 - Short Survey

AN - SCOPUS:84975502218

SN - 0304-3835

VL - 387

SP - 77

EP - 83

JO - Cancer Letters

JF - Cancer Letters

ER -

Challenges and opportunities for siRNA-based cancer treatment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this